Utama › Sklerosis Pelbagai › Wilayah Columbia › Washington
Kajian klinikal Sklerosis Pelbagai di Washington, DC
13 kajian untuk Sklerosis Pelbagai sedang mencari peserta di lokasi dalam dan sekitar Washington (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Mengambil pesertaFasa 1/2
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Mengambil pesertaFasa 1
- MedStar Georgetown University Hospital, Washington D.C.
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda · 7 mi jauh
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Mengambil pesertaKajian pemerhatian
- TG Therapeutics Investigational Trial Site, Washington D.C.
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
Mengambil pesertaFasa 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Mengambil pesertaFasa 1
- Research Site, Washington D.C.
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Mengambil pesertaFasa 3
- Georgetown University Hospital, Washington D.C.
- Medstar Washington Hosp Ctr, Washington D.C.
- Mid Atlantic Epilepsy and Sleep Ctr, Bethesda · 7 mi jauh
Pathological Basis of MRI Signal Changes in Multiple Sclerosis
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
Mengambil pesertaFasa 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Genes and Environment in Multiple Sclerosis
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- National Institute of Neurological Disorders and Stroke, Bethesda · 7 mi jauh
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
Mengambil pesertaKajian pemerhatian
- Evidera INC., Bethesda · 7 mi jauh
- Evidera, Bethesda · 7 mi jauh
Kajian Sklerosis Pelbagai di bandar lain
- New York City, NY17 kajian
- Chicago, IL15 kajian
- Boston, MA14 kajian
- Cleveland, OH9 kajian
- St. Louis, MO8 kajian
- Kansas City, KS8 kajian
- Birmingham, AL8 kajian
- San Francisco, CA8 kajian
- Columbus, OH7 kajian
- Aurora, CO7 kajian
- Baltimore, MD7 kajian
- Farmington Hills, MI6 kajian
Kajian lain di Washington
- Kanser (semua jenis)58 kajian
- Kanser Paru-paru Bukan Sel Kecil55 kajian
- Kanser Payudara46 kajian
- Kanser Metastatik43 kajian
- Kanser Paru-paru41 kajian
- Kanser Prostat38 kajian
- Obesiti33 kajian
- Kanser Kolorektal29 kajian
- Penyakit Kardiovaskular29 kajian
- Kanser Pundi Kencing26 kajian
- Leukemia Mieloid Akut24 kajian
- Limfoma23 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.